Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
Latest Information Update: 21 Jun 2023
At a glance
- Drugs Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; Aluminium hydroxide
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors China National Biotec Group
- 15 Jun 2023 Status changed from recruiting to completed.
- 22 Jan 2022 Planned End Date changed from 16 Sep 2021 to 15 Jul 2022.
- 26 May 2021 Results of an interim analysis published in the JAMA: the Journal of the American Medical Association